← All trials
NCT05901545
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2023
- Primary completion
- Aug 30, 2028
- Completion date
- Aug 30, 2029
- First posted
- Jun 13, 2023
- Last posted
- Oct 16, 2023
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Vanderbilt UniversityLead sponsor
- Vanderbilt UniversityOverall official - principal investigator
- Vanderbilt UniversityReponsible party - principal investigator
- American Cancer Society, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.